with adalimumab becoming the most commonly used b/tsDMARD. Researchers performed a serial cross-sectional study using ...
By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster ...
Celltrion USA has expanded access to ZYMFENTRA® (infliximab-dyyb), the first and only FDA-approved subcutaneous (SC) infliximab, to a significant share of the U.S. market ...
Treatment with CZP vs ADA may offer more consistent efficacy when used among patients with RA who have elevated RF levels.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback